MX2018012716A - Peptidos bioactivos pegilados y usos de los mismos. - Google Patents

Peptidos bioactivos pegilados y usos de los mismos.

Info

Publication number
MX2018012716A
MX2018012716A MX2018012716A MX2018012716A MX2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A MX 2018012716 A MX2018012716 A MX 2018012716A
Authority
MX
Mexico
Prior art keywords
bioactive peptides
subject
modified
positions
peg moiety
Prior art date
Application number
MX2018012716A
Other languages
English (en)
Inventor
G Peri Krishna
Original Assignee
Griffon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffon Pharmaceuticals Inc filed Critical Griffon Pharmaceuticals Inc
Publication of MX2018012716A publication Critical patent/MX2018012716A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente péptidos bioactivos que se modifican en una o más posiciones con una porción de PEG. Un ejemplo de este péptido bioactivo PEGilado es un análogo de GHRH que se modifica en una o más posiciones con una porción PEG. También se describen sales farmacéuticamente aceptables de los mismos y composiciones farmacéuticas que comprenden tales análogos o sales de los mismos, así como métodos, kits y usos de los mismos, por ejemplo para inducir o estimular la secreción de la hormona de crecimiento en un sujeto y para diagnosticar, prevenir o tratar afecciones deficientes de GH en un sujeto.
MX2018012716A 2016-04-19 2017-04-18 Peptidos bioactivos pegilados y usos de los mismos. MX2018012716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2018012716A true MX2018012716A (es) 2019-02-11

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012716A MX2018012716A (es) 2016-04-19 2017-04-18 Peptidos bioactivos pegilados y usos de los mismos.

Country Status (17)

Country Link
US (2) US9988428B2 (es)
EP (1) EP3445778B1 (es)
JP (1) JP7134093B2 (es)
KR (1) KR102520348B1 (es)
CN (1) CN109153712B (es)
AU (1) AU2017254754B2 (es)
BR (1) BR112018070929A2 (es)
CA (1) CA3021231A1 (es)
DK (1) DK3445778T3 (es)
ES (1) ES2824781T3 (es)
HU (1) HUE052802T2 (es)
IL (1) IL262356B2 (es)
MX (1) MX2018012716A (es)
PT (1) PT3445778T (es)
RU (1) RU2748576C2 (es)
SG (1) SG11201808880PA (es)
WO (1) WO2017181277A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253828A1 (en) 2019-03-29 2021-10-28 The General Hospital Corporation GHRH or analogues thereof for use in treatment of hepatic disease
WO2022075216A1 (ja) 2020-10-09 2022-04-14 オートリブ ディベロップメント エービー エアバッグ装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
ZA914983B (en) 1990-06-29 1992-03-25 Hoffmann La Roche His-grf-analogs
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
WO1992018531A1 (en) 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
WO1996032126A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
ES2163020T3 (es) 1995-05-26 2002-01-16 Theratechnologies Inc Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CN1635898A (zh) 1999-07-26 2005-07-06 贝勒医学院 超级活性的猪生长激素释放激素类似物
WO2002028437A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
KR20050071498A (ko) 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1628676A1 (en) 2003-05-29 2006-03-01 Theratechnologies Inc. Grf analog compositions and their use
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
JP2011511778A (ja) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
CA2745499A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
KR20140027284A (ko) * 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
US20170037105A1 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
EP3445778B1 (en) 2020-07-15
CN109153712A (zh) 2019-01-04
EP3445778A1 (en) 2019-02-27
CN109153712B (zh) 2022-09-16
US10918730B2 (en) 2021-02-16
HUE052802T2 (hu) 2021-05-28
KR102520348B1 (ko) 2023-04-10
RU2748576C2 (ru) 2021-05-27
CA3021231A1 (en) 2017-10-26
US20190209699A1 (en) 2019-07-11
IL262356A (en) 2018-11-29
AU2017254754A1 (en) 2018-11-01
KR20180135016A (ko) 2018-12-19
ES2824781T3 (es) 2021-05-13
WO2017181277A1 (en) 2017-10-26
US9988428B2 (en) 2018-06-05
RU2018140501A3 (es) 2020-09-08
PT3445778T (pt) 2020-10-15
BR112018070929A2 (pt) 2019-02-26
DK3445778T3 (da) 2020-10-12
IL262356B2 (en) 2023-06-01
US20170296628A1 (en) 2017-10-19
SG11201808880PA (en) 2018-11-29
EP3445778A4 (en) 2019-05-01
JP2019516675A (ja) 2019-06-20
RU2018140501A (ru) 2020-05-19
AU2017254754B2 (en) 2021-02-04
JP7134093B2 (ja) 2022-09-09

Similar Documents

Publication Publication Date Title
MX2023003875A (es) Formulacion de una vacuna peptidica.
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
CL2018000215A1 (es) Uso de variantes de péptido natriuretico de tipo c para tratar displasia esquelética.
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2018012716A (es) Peptidos bioactivos pegilados y usos de los mismos.
EA201990298A1 (ru) Способы и композиции для лечения рака
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2016011852A (es) Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
AR112785A1 (es) Composición de péptidos asociados a tumores proliferativos e inmunógeno anti-cáncer relacionado para el tratamiento de cánceres de pulmón y otros cánceres
ZA202100880B (en) Short cyclic peptides for the treatment of graves' disease
MX2020013924A (es) Composicion inmunogena para paratuberculosis.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
CR20210363A (es) Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias
WO2018031730A3 (en) Peptide inhibitors of phosphoglycerate mutase and methods of use
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста